7 Best Peptides for Andropause

What to Know Before Choosing a Peptide for Andropause

Andropause describes the gradual decline in testosterone and related hormones that most men experience with age. Leydig cells in the testes produce less testosterone, the hypothalamic-pituitary-gonadal axis becomes less responsive, and rising levels of sex hormone-binding globulin bind up more of what is produced, leaving less of it biologically available. The symptoms that follow from that cascade, fatigue, reduced libido, muscle loss, brain fog, and mood changes, are what bring most men into the conversation about peptide-based interventions.

The compounds in this guide each target a specific point in that cascade. Some act at the hypothalamus, the top of the signaling chain. Some act at the pituitary. Some go directly to the testes. One addresses the parallel decline in growth hormone that often accompanies testosterone loss, and one works entirely outside the testosterone axis to address sexual function symptoms through the central nervous system. A compound earns a slot here because people use it or are actively discussing it for andropause, period. FDA approval status, telemedicine availability, and research-chemical status are all irrelevant to inclusion. Evidence strength is stated honestly inside each entry, not used as a filter.

The numbers in front of each entry are an ordering, not a ranking. They reflect how prominently each compound appears in research and documented real-world use for andropause, not a judgment that the first compound is better for any individual than the seventh. The right compound for a given person depends on their specific hormonal picture, what else they are taking, and what outcome they are prioritizing.

One important framing note: no published human clinical trial has specifically evaluated any of these compounds for andropause as a primary endpoint. The evidence described in each entry comes from trials in related conditions, mechanistic reasoning from HPG axis physiology, and real-world use in men's health contexts. Some entries have substantially more backing than others, and those differences are laid out plainly throughout.

1. HCG: The Most Clinically Established Testicular Stimulator

Human chorionic gonadotropin is a glycoprotein hormone that structurally mimics luteinizing hormone, the pituitary signal that tells the testes to produce testosterone. Where most HPG-axis interventions work by nudging the brain to send better signals, HCG bypasses the hypothalamus and pituitary entirely and goes straight to the Leydig cells. It binds the same receptor that LH binds, triggering testosterone synthesis directly at the testicular level.

That directness makes HCG useful in two distinct andropause scenarios. The first is as a standalone approach for men with low testosterone who want to stimulate endogenous production without using exogenous androgens. The second, and more common in practice, is as an adjunct alongside testosterone replacement therapy. When a man takes exogenous testosterone, the pituitary senses elevated levels and stops releasing LH, which causes the testes to stop working and eventually atrophy. Adding HCG maintains the LH-receptor signal to the testes, preserving their function and keeping intratesticular testosterone levels up, something exogenous testosterone cannot replicate on its own.

HCG carries FDA approval for specific indications including male hypogonadism caused by pituitary disease, cryptorchidism in boys, and female fertility treatment. Its off-label use for general andropause and testosterone optimization is widespread across men's health clinics and telemedicine platforms. The clinical history here is long, and the safety profile is well-characterized. The main concern is estradiol elevation: the additional testosterone HCG stimulates can be converted to estrogen via aromatase, which occasionally requires management. Testicular sensitivity and polycythemia with prolonged use are also monitored in clinical practice.

For men with andropause symptoms who want to keep the testes engaged rather than replace their function entirely, HCG has more real-world clinical use and a deeper evidence base than anything else on this list.

2. Gonadorelin: Stimulating the Axis from the Hypothalamus

Gonadorelin is a synthetic form of gonadotropin-releasing hormone, the master signal produced by the hypothalamus that sets the entire testosterone-production cascade in motion. GnRH tells the pituitary to release LH and FSH. LH tells the Leydig cells to make testosterone. FSH supports sperm production. Gonadorelin steps in as a precise stand-in for that hypothalamic signal.

In the andropause context, gonadorelin is used in two main ways. Men on testosterone replacement therapy use it to keep the pituitary-testicular axis active, preventing the testicular atrophy that exogenous testosterone causes by suppressing natural LH secretion. Some men also use it as a component of HPG-axis restoration protocols when the goal is to rebuild endogenous testosterone production rather than replace it.

The critical point about gonadorelin is that how it is administered matters enormously. Pulsatile dosing, spaced to mimic the hypothalamus's natural rhythmic GnRH release, keeps the pituitary receptors responsive and produces the intended LH and FSH stimulation. Continuous or sustained administration does the opposite: it overwhelms the receptors, causes desensitization, and paradoxically suppresses LH and testosterone. This is not a theoretical concern; it is the documented mechanism behind GnRH agonist therapy used to suppress testosterone in prostate cancer treatment. The distinction between pulsatile and continuous administration is why gonadorelin requires medical supervision rather than self-directed use.

Gonadorelin has established pharmaceutical history in the US, previously approved under brand names for specific indications, and is currently available through compounding pharmacies for off-label men's health use. No randomized controlled trial has evaluated it specifically for andropause symptom management, but the mechanistic rationale for its use in maintaining HPG axis function alongside TRT is well-grounded in endocrinology, and it is used off-label under physician supervision across men's health practices.

3. Enclomiphene: The SERM Approach to Raising Testosterone

Enclomiphene is the trans-isomer of clomiphene citrate. It is not a peptide in the conventional sense but a selective estrogen receptor modulator, a small molecule drug that works through the HPG axis in a way that makes it directly comparable to the peptide-based options here. It appears consistently in andropause-adjacent hormone optimization discussions and is actively prescribed by men's health and telemedicine clinicians for this purpose.

Its mechanism is essentially a trick on the hypothalamus. Testosterone production is partly regulated by estrogen feedback: as estrogen levels rise, the hypothalamus senses them and reduces GnRH secretion, which eventually dials back testosterone production. Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary, removing that negative feedback. The hypothalamus perceives lower estrogen than is actually present, increases GnRH secretion, the pituitary releases more LH and FSH, and the testes respond by producing more testosterone. The man's own HPG axis does the work.

The advantage enclomiphene holds over exogenous testosterone is that it preserves the axis rather than suppressing it. Men who want to raise testosterone while maintaining fertility, and particularly those who are not yet severely deficient but want to address the compounding factor of increased estradiol conversion that comes with age, are drawn to SERMs for this reason. It is taken orally, which is also a practical advantage for those averse to injections.

Enclomiphene was investigated for male hypogonadism under the brand name Androxal and did not receive full FDA approval for that indication, though it demonstrated efficacy in clinical trials. It remains available off-label through compounding pharmacies and men's health platforms. The evidence here is stronger than most compounds on this list for testosterone elevation specifically, coming from actual clinical trial data in men. For men with andropause whose primary concern involves estradiol excess reducing testosterone bioavailability, enclomiphene's mechanism directly addresses that compounding factor.

4. PT-141: For the Sexual Dysfunction Component

PT-141, also called bremelanotide, occupies a different lane than the HPG-axis compounds above. It does not work on testosterone production at all. It works directly on the central nervous system, targeting melanocortin receptors in the brain to increase dopamine-driven sexual desire. For men whose primary andropause complaint is loss of libido or erectile dysfunction, PT-141 addresses that specific symptom through a mechanism that has nothing to do with circulating testosterone levels.

The clinical evidence for PT-141 is the most robust of any compound on this list for a specific andropause-related symptom. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and its off-label use in men for libido loss and erectile dysfunction is well-established in men's health practice. Clinical data showed meaningful response in roughly one-third of men who had previously failed PDE5 inhibitors, the class that includes sildenafil and tadalafil. That finding matters: PT-141 works through a completely different pathway than those drugs, making it relevant specifically for men whose erectile dysfunction has a central or desire-based component rather than a purely vascular one.

PT-141 does not fix the underlying hormonal deficit of andropause. It addresses one of the symptoms. Men who find that libido and sexual function are their dominant complaint, particularly when testosterone-focused interventions have not fully resolved the issue, are the ones who most often reach for it in men's health protocols. The side effect profile is well-characterized from clinical trials: nausea is the most common, followed by flushing and transient blood pressure increase. The compound is administered before sexual activity rather than on a daily maintenance schedule.

5. Kisspeptin-10: Targeting the Upstream Switch

Kisspeptin-10 sits at the very top of the reproductive hormonal hierarchy, upstream of GnRH itself. Kisspeptin neurons in the hypothalamus act as gatekeepers of GnRH release: without a kisspeptin signal arriving at GnRH neurons via the KISS1R receptor, GnRH neurons stay silent. Kisspeptin is essentially the switch that turns on the entire HPG axis, and research in endocrinology has established that kisspeptin signaling declines with age in men, which likely contributes to the reduced GnRH pulsatility and downstream testosterone suppression that characterizes andropause.

The theoretical appeal for andropause is genuine. If the problem starts at the very top of the axis, intervening there restores the cascade in a way that mirrors natural physiology more closely than any downstream intervention. Because Kisspeptin-10 stimulates GnRH pulsatility rather than replacing it, the resulting downstream testosterone production maintains the natural pulse rhythm that supports receptor sensitivity and healthy hormonal balance.

In practice, Kisspeptin-10 is an experimental compound in the andropause context. Human studies have examined kisspeptin's role in fertility and puberty disorders, establishing that the mechanism is real and functional in humans. However, no published human clinical trial has specifically studied Kisspeptin-10 for andropause symptom management as of 2026. Its use in men's health protocols is community-reported and largely experimental, appearing in longevity and hormone optimization stacks among practitioners and biohackers working at the frontier of HPG axis interventions. The evidence is mechanistically compelling but clinically thin for this specific application. Dosing is not standardized for andropause use, and long-term safety data in this context does not yet exist. It is a compound worth understanding for the conceptual clarity it brings to how the HPG axis works, and because it appears with increasing frequency in forward-looking protocol discussions, but one that warrants clear-eyed acknowledgment of how early the clinical picture is.

6. CJC-1295 with Ipamorelin: Addressing the Somatopause Layer

Andropause and somatopause often arrive together. Somatopause is the parallel age-related decline in growth hormone and IGF-1, and it produces overlapping symptoms: muscle loss, increased visceral fat, poor sleep quality, fatigue, and reduced vitality. For many men, what they experience as andropause is partly driven by testosterone decline and partly by the simultaneous decline in growth hormone output. The CJC-1295 and Ipamorelin combination addresses the somatopause layer.

CJC-1295 is a growth hormone-releasing hormone analog. It binds GHRH receptors on the pituitary, which are proteins that act as the on-switch for growth hormone secretion, and stimulates GH release with an extended half-life compared to natural GHRH. Ipamorelin is a growth hormone-releasing peptide, a ghrelin mimetic that binds ghrelin receptors on the pituitary and hypothalamus to trigger separate GH pulses. The two compounds work through different receptor systems on the same gland, and when combined their effect on growth hormone output is substantially greater than either produces alone. This pairing has become the standard secretagogue combination in anti-aging and men's health protocols for that reason.

The benefits men report from this combination for andropause-adjacent symptoms are among the most consistently described in community use: improved deep sleep, reduced body fat particularly around the abdomen, improved recovery from exercise, and better energy levels. These are user-reported outcomes without a published clinical trial specifically targeting andropause, but the physiological rationale is sound and the combination has a well-developed body of community experience behind it.

CJC-1295 and Ipamorelin are not FDA-approved as finished drug products and are available through compounding pharmacies. The FDA's approach to peptide compounding was under active review as of mid-2026. Adverse events reported in community use include injection site reactions, water retention, and headache. A small number of anaphylaxis cases have been reported with this combination, which underscores the importance of medical supervision.

7. Testagen: The Bioregulator Approach to Testicular Function

Testagen is a short synthetic tetrapeptide, four amino acids in sequence, developed within the Russian peptide bioregulator research tradition, primarily out of the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to a class of compounds called peptide bioregulators, short sequences proposed to act as tissue-specific normalizers. The proposed mechanism is that these short sequences penetrate cells and interact with DNA to restore normal gene expression patterns in the target tissue. Testagen's target is testicular tissue, specifically the Leydig cells responsible for testosterone synthesis.

No human clinical trial data on Testagen for andropause has been published in widely indexed Western medical literature as of 2026. The available evidence originates from Russian-language research and the clinical practice of bioregulator proponents, and it has not been independently replicated in large-scale randomized controlled trials. What exists is a theoretical mechanism, a framework of small-scale studies from a specific research tradition, and the reported use of Testagen by men pursuing bioregulator-based approaches to hormonal aging, often as part of broader protocols that include other bioregulators targeting different organ systems.

Testagen earns its slot here because it is genuinely discussed and used in the andropause context within bioregulator communities and some integrative medicine practices. The honest assessment is that its evidence base is preliminary by Western clinical standards, and purity and quality of commercial products vary significantly given its unregulated status. Men drawn to bioregulator protocols typically value their proposed tissue-specificity and what proponents describe as a normalizing rather than stimulating mechanism, which is conceptually distinct from the more direct hormonal interventions higher on this list. Anyone considering Testagen should approach it with clear awareness of both the genuine uncertainty about its clinical effects and the sourcing risks inherent in unregulated research compounds.

How These Peptides Compare

Frequently Asked Questions

Are these compounds legal to obtain?

Legal status varies significantly across this list. HCG and PT-141 are FDA-approved and available by prescription. Gonadorelin and enclomiphene are available off-label through compounding pharmacies and men's health telemedicine platforms, which operate legally but outside standard FDA-approved indications. CJC-1295 and Ipamorelin are not FDA-approved as finished drugs and exist in a compounding gray zone that was under active regulatory review in 2026. Testagen and Kisspeptin-10 are research compounds with no approved status in the US. A prescribing clinician is the right starting point for anyone exploring any of these options.

Do these compounds replace testosterone therapy?

Most of the compounds on this list stimulate the body's own testosterone production rather than replacing testosterone from outside. HCG, Gonadorelin, Enclomiphene, and Kisspeptin-10 each work through the HPG axis to raise endogenous testosterone, which matters for men who want to preserve fertility or avoid suppressing their own production. PT-141 does not affect testosterone at all and addresses sexual function through a separate pathway. Whether any of these is appropriate as an alternative to traditional testosterone replacement depends on how significantly testosterone has declined and what the full clinical picture looks like.

How long before these compounds show results?

The answer varies considerably by compound and by which symptom is the target. PT-141 produces effects within hours of administration. HCG and enclomiphene typically produce measurable changes in testosterone levels within a few weeks of consistent use in men who respond. The CJC-1295 and Ipamorelin combination is commonly reported to produce sleep and body composition improvements over six to twelve weeks. Kisspeptin-10 and Testagen have no well-established clinical timeline for andropause applications because the evidence base for those specific uses is too early to offer reliable numbers.

Is it safe to combine several of these at once?

Combining HPG-axis compounds is something practitioners do in clinical protocols, but it introduces complexity that multiplies the need for monitoring. Using HCG alongside gonadorelin stimulates testicular and pituitary levels of the axis simultaneously, and understanding how those signals interact requires tracking LH, FSH, testosterone, and estradiol together. Adding a GH secretagogue stack on top of that adds IGF-1 to the picture. Some combinations are well-described in men's health clinical settings, and stacking without baseline bloodwork and ongoing monitoring is the scenario where adverse outcomes become likely. Medical oversight is not optional here.

What bloodwork matters before starting any of these?

Before beginning any compound that touches testosterone or growth hormone production, a baseline panel should include total testosterone, free testosterone, sex hormone-binding globulin, LH, FSH, estradiol, IGF-1, PSA, a complete metabolic panel, and a complete blood count. PSA is particularly important before starting anything that increases testosterone, because elevated testosterone can promote growth of undetected prostate cancer. The baseline also gives a clinician the information needed to identify where in the HPG axis the problem actually sits, which determines which intervention makes sense.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for andropause in one place.